Multiple Myeloma Symposium: Diagnosis and Risk Assessment | Dana-Farber Cancer Institute

The Latest Insights on Immune Therapies in Myeloma | 2023 IMF Patient and Family SeminarПодробнее

Future Directions for Novel and Next Generation Therapy in Multiple Myeloma | Dana-FarberПодробнее

The Evolution of Systemic Therapy for Newly Diagnosed Multiple Myeloma, Dana-Farber Cancer InstituteПодробнее

Updates on AL Amyloidosis Treatment: What is New in 2023 | Dana-Farber Cancer InstituteПодробнее

Myeloma 101: Diagnosis, Prognosis & Risk | Dana-Farber Cancer InstituteПодробнее

Update in Multiple MyelomaПодробнее

Current and Future Directions for Novel Therapy for Multiple Myeloma: Paul G. Richardson, MDПодробнее

Multiple Myeloma 101: Diagnosis, Prognosis, and Risk: Nikhil C. Munshi, MDПодробнее

Symptom Management in Multiple Myeloma: Shonali Midha, MDПодробнее

Update on Multiple Myeloma Treatment: Kenneth C. Anderson, MDПодробнее

New Directions in Treating Multiple Myeloma in the Era of Novel AgentsПодробнее

Symptom Management in Multiple MyelomaПодробнее

Current and Future Treatment of Multiple MyelomaПодробнее

Smoldering Multiple MyelomaПодробнее

Updates on Managing Bone Disease in Multiple MyelomaПодробнее

Dana-Farber’s Presidential Symposium: Panel on Precision Prevention & Early DetectionПодробнее

2019 Multiple Myeloma Symposium | Q&A with Clifton Mo, MDПодробнее

2019 Multiple Myeloma Symposium | Symptom ManagementПодробнее

2019 Multiple Myeloma Symposium | Novel and Next Generation TherapyПодробнее

2019 Multiple Myeloma Symposium | Diagnosis, Prognosis & RiskПодробнее